Publications by authors named "Marianna Zappimbulso"
Article Synopsis
- Steatotic liver disease linked to metabolic dysfunction (MASLD) is prevalent in up to 30% of adults and is often associated with obesity and metabolic syndrome.
- The study involved 42 patients split into three groups receiving different treatments: dietary advice only (CG), dietary advice plus aerobic exercise (AE + DA), and dietary advice plus high-intensity interval training (HIIT + DA).
- Results showed that both exercise groups had significant reductions in cortisol levels, with HIIT + DA showing the greatest effects, and a notable decrease in hepatic steatosis was also observed, particularly in the AE + DA group.
Daily Orange Consumption Reduces Hepatic Steatosis Prevalence in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: Exploratory Outcomes of a Randomized Clinical Trial.
Nutrients
September 2024
: Consumption of flavonoid-rich orange juice has been shown to reduce adiposity and liver steatosis in murine models of diet-induced obesity. However, little is known about the effects of whole orange intake, independent of body weight changes, on liver function and steatosis in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). The goal is to understand the direct impact of orange consumption on metabolic health.
View Article and Find Full Text PDFArticle Synopsis
- Obesity and metabolic syndrome are closely associated with steatotic liver disease (SLD), which is the most common chronic liver disease, and lifestyle changes, especially a very low-calorie ketogenic diet (VLCKD), may help prevent this condition.
- A study involving 112 overweight or obese participants examined the impacts of VLCKD on steatosis and fibrosis, revealing significant baseline differences between men and women regarding liver health, metabolic indicators, and body composition.
- After the VLCKD intervention, both genders showed improvements in various health markers; however, men had initially higher levels of liver steatosis and fibrosis, and even after treatment, these gender-specific differences in liver health persisted.
Background: Sustained virological response (SVR12) rates at 12 weeks after treatment for HCV-infected patients with decompensated cirrhosis are used when referring to those with moderate functional impairment, while few data are available for those with more severe impairment. The use of the cirrhosis staging system proposed by D'Amico might provide new insights on timing for antiviral therapy.
Methods: We investigated efficacy (SVR12), safety, and post-treatment variations in clinical and laboratory parameters in 2612 patients with advanced fibrosis (n=575) or cirrhosis (n=2037).
Article Synopsis
- Interferon-based therapies for HCV recurrence after liver transplantation have been largely ineffective and face safety issues with other treatments like boceprevir and telaprevir.
- A study assessed the efficacy and safety of intravenous silibinin in 20 patients who did not respond to previous treatments; patients were randomly assigned to receive either silibinin or placebo.
- Results showed that silibinin significantly reduced viral load after 14 days of treatment, was well tolerated with only minor side effects, and did not require adjustments to immunosuppressive medication levels.